{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:13:13Z","timestamp":1788826393657,"version":"build-2803163510"},"reference-count":149,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["NIHR135138"],"award-info":[{"award-number":["NIHR135138"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"<jats:sec id=\"abs1-1\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Atopic dermatitis is a chronic relapsing inflammatory skin condition. One of the most common skin disorders in children, atopic dermatitis typically manifests before the age of 5 years, but it can develop at any age. Atopic dermatitis is characterised by dry, inflamed skin accompanied by intense itchiness (pruritus).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-2\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To appraise the clinical and cost effectiveness of abrocitinib, tralokinumab and upadacitinib within their marketing authorisations as alternative therapies for treating moderate-to-severe atopic dermatitis compared to systemic immunosuppressants (first-line ciclosporin A or second-line dupilumab and baricitinib).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-3\">\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Studies were identified from an existing systematic review (search date 2019) and update searches of electronic databases (MEDLINE, EMBASE, CENTRAL) to November 2021, from bibliographies of retrieved studies, clinical trial registers and evidence provided by the sponsoring companies of the treatments under review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-4\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review of the clinical effectiveness literature was carried out and a network meta-analysis undertaken for adults and adolescents at different steps of the treatment pathway. The primary outcome of interest was a combined response of Eczema Area and Severity Index 50 + Dermatology Life Quality Index \u2265 4; where this was consistently unavailable for a step in the pathway, an analysis of Eczema Area and Severity Index 75 was conducted. A de novo economic model was developed to assess cost effectiveness from the perspective of the National Health Service in England. The model structure was informed through systematic review of the economic literature and by consulting clinical experts. Effectiveness data were obtained from the network meta-analysis. Costs and utilities were obtained from the evidence provided by sponsoring companies and standard UK sources.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-5\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Network meta-analyses indicate that abrocitinib 200 mg and upadacitinib 30 mg may be more effective, and tralokinumab may be less effective than dupilumab and baricitinib as second-line systemic therapies. Abrocitinib 100 mg and upadacitinib 15 mg have a more similar effectiveness to dupilumab. Upadacitinib 30 and 15 mg are likely to be more effective than ciclosporin A as a first-line therapy. Upadacitinib 15 mg, abrocitinib 200 and 100 mg may be more effective than dupilumab in adolescents. The cost effectiveness of abrocitinib and upadacitinib for both doses is dependent on the subgroup of interest. Tralokinumab can be considered cost-effective as a second-line systemic therapy owing to greater cost savings per quality-adjusted life-year lost.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-6\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The primary strength of the analysis of the three new drugs compared with current practice for each of the subpopulations is the consistent approach to the assessment of clinical and cost effectiveness. However, the conclusions are limited by the high uncertainty around the clinical effectiveness and lack of data for the primary outcome for comparisons with baricitinib and for the adolescent and adult first-line populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-7\">\n                    <jats:title>Future work and limitations<\/jats:title>\n                    <jats:p>The most significant limitation that Eczema Area and Severity Index 50\u2005+\u2005Dermatology Life Quality Index\u2005\u2265\u20054 could not be obtained for the adolescent and adult first-line systemic treatment populations is due to a paucity of data for dupilumab and ciclosporin A. A comparison of the new drugs against one another in addition to current practice would be beneficial to provide a robust view on which treatments are the most cost-effective.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-8\">\n                    <jats:title>Study registration<\/jats:title>\n                    <jats:p>This study is registered as PROSPERO CRD42021266219.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"abs1-9\">\n                    <jats:title>Funding<\/jats:title>\n                    <jats:p>\n                      This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis programme (NIHR award ref: 135138) and is published in full in\n                      <jats:italic>Health Technology Assessment<\/jats:italic>\n                      ; Vol. 28, No. 4. See the NIHR Funding and Awards website for further award information.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3310\/lexb9006","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T04:48:03Z","timestamp":1688446083000},"page":"1-113","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9049-3421","authenticated-orcid":true,"given":"Steven J","family":"Edwards","sequence":"first","affiliation":[{"name":"Director of Health Technology Assessment, BMJ-TAG, BMJ, BMA House, Tavistock Square, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3855-4853","authenticated-orcid":true,"given":"Charlotta","family":"Karner","sequence":"additional","affiliation":[{"name":"Clinical Evidence Manager, BMJ-TAG, BMJ, BMA House, Tavistock Square, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8041-0346","authenticated-orcid":true,"given":"Tracey","family":"Jhita","sequence":"additional","affiliation":[{"name":"Health Economics Manager, BMJ-TAG, BMJ, BMA House, Tavistock Square, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7051-5112","authenticated-orcid":true,"given":"Samantha","family":"Barton","sequence":"additional","affiliation":[{"name":"Principal Clinical Evidence Analyst, BMJ-TAG, BMJ, BMA House, Tavistock Square, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9365-0384","authenticated-orcid":true,"given":"Gemma","family":"Marceniuk","sequence":"additional","affiliation":[{"name":"Senior Health Economist, BMJ-TAG, BMJ, BMA House, Tavistock Square, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-074X","authenticated-orcid":true,"given":"Zenas Z N","family":"Yiu","sequence":"additional","affiliation":[{"name":"NIHR Clinical Lecturer in Dermatology, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2328-4926","authenticated-orcid":true,"given":"Miriam","family":"Wittmann","sequence":"additional","affiliation":[{"name":"Associate Professor in Inflammatory Skin Diseases, University of Leeds, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2024,1]]},"reference":[{"key":"key2026050211082500_ref1-bib1","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13223-018-0281-6","article-title":"Atopic dermatitis","volume":"14","author":"Kapur","year":"2018","journal-title":"Allergy Asthma Clin Immunol"},{"key":"key2026050211082500_ref2-bib2","doi-asserted-by":"crossref","first-page":"354250","DOI":"10.1155\/2014\/354250","article-title":"Atopic dermatitis: natural history, diagnosis, and treatment","volume":"2014","author":"Thomsen","year":"2014","journal-title":"ISRN Allergy"},{"key":"key2026050211082500_ref3-bib3","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/09546634.2019.1655137","article-title":"Atopic dermatitis epidemiology and unmet need in the United Kingdom","volume":"31","author":"Cork","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"key2026050211082500_ref4-bib4","volume-title":"Atopic Dermatitis and Eczema","author":"Patient","year":"2021"},{"key":"key2026050211082500_ref5-bib5","first-page":"96","article-title":"Molecular genetic of atopic dermatitis: an update","volume":"10","author":"Al-Shobaili","year":"2016","journal-title":"Int J Health Sci (Qassim)"},{"key":"key2026050211082500_ref6-bib6","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1242\/jcs.033969","article-title":"Filaggrin in the frontline: role in skin barrier function and disease","volume":"122","author":"Sandilands","year":"2009","journal-title":"J Cell Sci"},{"key":"key2026050211082500_ref7-bib7","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jaci.2007.08.067","article-title":"Toward a major risk factor for atopic eczema: meta-analysis of filaggrin polymorphism data","volume":"120","author":"Baurecht","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"key2026050211082500_ref8-bib8","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/ng1767","article-title":"Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis","volume":"38","author":"Palmer","year":"2006","journal-title":"Nat Genet"},{"key":"key2026050211082500_ref9-bib9","volume-title":"Atopic Dermatitis: From Physiopathology to the Clinics","author":"Figueras-Nart","year":"2019"},{"key":"key2026050211082500_ref10-bib10","volume-title":"Atopic Eczema","author":"British Association of Dermatologists","year":"2020"},{"key":"key2026050211082500_ref11-bib11","doi-asserted-by":"crossref","first-page":"k1786","DOI":"10.1136\/bmj.k1786","article-title":"Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study","volume":"361","author":"Silverwood","year":"2018","journal-title":"BMJ"},{"key":"key2026050211082500_ref12-bib12","volume-title":"Dupilumab for Treating Moderate to Severe Atopic Dermatitis: Technology Appraisal Guidance [TA534]","author":"National Institute for Health and Care Excellence (NICE)","year":"2018"},{"key":"key2026050211082500_ref14-bib14","first-page":"174","article-title":"Quality of life in patients with atopic dermatitis","volume":"104","author":"Koszoru","year":"2019","journal-title":"Cutis"},{"key":"key2026050211082500_ref15-bib15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2340\/00015555-3102","article-title":"Out-of-pocket costs for individuals with atopic eczema: a cross-sectional study in nine European Countries","volume":"99","author":"Zink","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"key2026050211082500_ref16-bib16","volume-title":"Skin Conditions in the UK: A Health Care Needs Assessment","author":"Schofield","year":"2009"},{"key":"key2026050211082500_ref17-bib17","volume-title":"Eczema","author":"National Institute for Health and Care Excellence (NICE)","year":"2021"},{"key":"key2026050211082500_ref18-bib18","doi-asserted-by":"crossref","first-page":"10S","DOI":"10.1177\/1203475418803628","article-title":"Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section II: tools for assessing the severity of atopic dermatitis","volume":"22","author":"Gooderham","year":"2018","journal-title":"J Cutan Med Surg"},{"key":"key2026050211082500_ref19-bib19","volume-title":"Core Outcomes for Trials","author":"Harmonising Outcomes for Eczema","year":"2021"},{"key":"key2026050211082500_ref20-bib20","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000365390","article-title":"Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data","volume":"230","author":"Basra","year":"2015","journal-title":"Dermatology"},{"key":"key2026050211082500_ref21-bib21","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1111\/bjd.15641","article-title":"Severity strata for Eczema Area and Severity Index (EASI), modified EASI, scoring atopic dermatitis (SCORAD), objective SCORAD, atopic dermatitis severity index and body surface area in adolescents and adults with atopic dermatitis","volume":"177","author":"Chopra","year":"2017","journal-title":"Br J Dermatol"},{"key":"key2026050211082500_ref22-bib22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/bjd.17744","article-title":"Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis","volume":"181","author":"Yosipovitch","year":"2019","journal-title":"Br J Dermatol"},{"key":"key2026050211082500_ref23-bib23","volume-title":"Eczema \u2013 Atopic Aczema","author":"Primary Care Dermatology Society","year":"2019"},{"key":"key2026050211082500_ref24-bib24","volume-title":"Atopic Eczema","author":"NHS","year":"2021"},{"key":"key2026050211082500_ref25-bib25","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/bjd.17587","article-title":"British Association of Dermatologists guidelines for the safe and effective prescribing of oral ciclosporin in dermatology 2018","volume":"180","author":"Berth-Jones","year":"2019","journal-title":"Br J Dermatol"},{"key":"key2026050211082500_ref26-bib26","volume-title":"Management of Atopic Eczema in Primary Care","author":"Scottish Intercollegiate Guidelines Network","year":"2011"},{"key":"key2026050211082500_ref27-bib27","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","article-title":"Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial","volume":"155","author":"Gooderham","year":"2019","journal-title":"JAMA Dermatol"},{"key":"key2026050211082500_ref28-bib28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"key":"key2026050211082500_ref29-bib29","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"},{"key":"key2026050211082500_ref30-bib30","doi-asserted-by":"crossref","first-page":"AB146","DOI":"10.1016\/j.jaci.2020.12.529","article-title":"Efficacy and safety of abrocitinib in adolescent patients with moderate-to-severe atopic dermatitis (AD): results from the phase 3 JADE TEEN study","volume":"147","author":"Eichenfield","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"key2026050211082500_ref31-bib31","doi-asserted-by":"crossref","first-page":"AB26","DOI":"10.1016\/j.jaad.2020.06.193","article-title":"15013 Dupilumab improves signs, symptoms, and quality of life in adolescents with moderate to severe atopic dermatitis","volume":"83","author":"Eichenfield","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"key2026050211082500_ref32-bib32","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"key":"key2026050211082500_ref33-bib33","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/all.13954","article-title":"Interleukin-13: targeting an underestimated cytokine in atopic dermatitis","volume":"75","author":"Bieber","year":"2020","journal-title":"Allergy"},{"key":"key2026050211082500_ref34-bib34","volume-title":"Tralokinumab Monotherapy for Adolescent Subjects with Moderate to Severe Atopic Dermatitis \u2013 ECZTRA 6 (ECZema TRAlokinumab Trial no. 6)","author":"ClinicalTrials.gov","year":"2021"},{"key":"key2026050211082500_ref35-bib35","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"key2026050211082500_ref36-bib36","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"key2026050211082500_ref37-bib37","volume-title":"Tralokinumab in Combination with Topical Corticosteroids in Japanese Subjects with Moderate-to-severe Atopic Dermatitis (ECZTRA 8)","author":"ClinicalTrials.gov","year":"2021"},{"key":"key2026050211082500_ref38-bib38","volume-title":"Tralokinumab in Combination with Topical Corticosteroids in Subjects with Severe Atopic Dermatitis \u2013 ECZTRA 7 (ECZTRA 7)","author":"ClinicalTrials.gov","year":"2021"},{"key":"key2026050211082500_ref39-bib39","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"key2026050211082500_ref40-bib40","volume-title":"A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants with Moderate to Severe Atopic Dermatitis (Heads Up)","author":"ClinicalTrials.gov","year":"2021"},{"key":"key2026050211082500_ref41-bib41","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"key2026050211082500_ref42-bib42","volume-title":"Abrocitinib, Tralokinumab and Upadacitinib for Treating Moderate to Severe Atopic Dermatitis. Final Scope","author":"National Institute for Health and Care Excellence (NICE)","year":"2021"},{"key":"key2026050211082500_ref43-bib43","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1046\/j.1365-2133.2002.04965.x","article-title":"Reliance on erythema scores may mask severe atopic dermatitis in black children compared with their white counterparts","volume":"147","author":"Ben-Gashir","year":"2002","journal-title":"Br J Dermatol"},{"key":"key2026050211082500_ref44-bib44","first-page":"804","article-title":"Efficacy of dupilumab in different racial subgroups of adults with moderate-to-severe atopic dermatitis in three randomized, placebo-controlled phase 3 trials","volume":"18","author":"Alexis","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"key2026050211082500_ref45-bib45","unstructured":"National Institute for Health and Care Excellence (NICE). Resource Impact Report: Baricitinib for Treating Moderate to Severe Atopic Dermatitis (TA681). 2021. URL: www.nice.org.uk\/guidance\/ta681\/resources\/resource-impact-report-pdf-9021362653 (accessed 11 October 2021)."},{"key":"key2026050211082500_ref46-bib46","volume-title":"Resource Impact Report: Dupilumab for Treating Moderate to Severe Atopic Dermatitis (TA534)","author":"National Institute for Health and Care Excellence (NICE)","year":"2018"},{"key":"key2026050211082500_ref47-bib47","article-title":"Systemic treatments for eczema: a network meta-analysis","volume":"9","author":"Sawangjit","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"key2026050211082500_ref48-bib48","volume-title":"Abrocitinib, Tralokinumab and Upadacitinib for Treating Moderate to Severe Atopic Dermatitis. Protocol for Multiple Technology Appraisal","author":"BMJ-TAG","year":"2021"},{"key":"key2026050211082500_ref50-bib50","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"key2026050211082500_ref51-bib51","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/hir.12269","article-title":"Translating the Cochrane EMBASE RCT filter from the Ovid interface to Embase.com: a case study","volume":"36","author":"Glanville","year":"2019","journal-title":"Health Info Libr J"},{"key":"key2026050211082500_ref52-bib52","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"key2026050211082500_ref53-bib53","volume-title":"NICE DSU Technical Support Document 1: Introduction to Evidence Synthesis for Decision Making","author":"Dias","year":"2012"},{"key":"key2026050211082500_ref54-bib54","volume-title":"NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-analysis of Randomised Controlled Trials","author":"Dias","year":"2011"},{"key":"key2026050211082500_ref56-bib56","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/sim.6381","article-title":"Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis","volume":"34","author":"Turner","year":"2015","journal-title":"Stat Med"},{"key":"key2026050211082500_ref57-bib57","volume-title":"NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials","author":"Dias","year":"2011"},{"key":"key2026050211082500_ref58-bib58","article-title":"Safety of dupilumab in moderate-to-severe atopic dermatitis patients inadequately controlled with, intolerant to, or inadvisable for cyclosporine-A: laboratory findings from the liberty-ad-caf\u00e9 trial","volume":"12","author":"Reich","year":"2020","journal-title":"J Dermatol Nurses Assoc"},{"key":"key2026050211082500_ref59-bib59","article-title":"Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults","volume":"12","author":"Zheng","year":"2020","journal-title":"J Dermatol Nurses Assoc"},{"key":"key2026050211082500_ref60-bib60","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.jid.2018.03.562","article-title":"The Janus kinase 1 (JAK1) inhibitor PF-04965842 reduces signs and symptoms of moderate to severe atopic dermatitis (AD)","volume":"138","author":"Gooderham","year":"2018","journal-title":"J Investig Dermatol"},{"key":"key2026050211082500_ref61-bib61","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0140-6736(91)90134-B","article-title":"Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis","volume":"338","author":"Sowden","year":"1991","journal-title":"Lancet"},{"key":"key2026050211082500_ref62-bib62","volume-title":"Royal Society of Medicine International Congress and Symposium Series Vol 192 Athens","author":"Allen","year":"1991"},{"key":"key2026050211082500_ref63-bib63","first-page":"16","article-title":"Cyclosporin in severe adult atopic dermatitis \u2013 a multi-centre, double-blind, placebo-controlled crossover study","volume":"125","author":"Berth Jones","year":"1991","journal-title":"Br J Dermatol"},{"key":"key2026050211082500_ref64-bib64","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2133.1994.tb02936.x","article-title":"Maintenance treatment with cyclosporin in atopic eczema","volume":"130","author":"Munro","year":"1994","journal-title":"Br J Dermatol"},{"key":"key2026050211082500_ref65-bib65","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2133.1993.tb03170.x","article-title":"Cyclosporin greatly improves the quality of life of adults with severe atopic dermatitis. A randomized, double-blind, placebo-controlled trial","volume":"129","author":"Salek","year":"1993","journal-title":"Br J Dermatol"},{"key":"key2026050211082500_ref66-bib66","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2133.1994.tb13111.x","article-title":"Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study","volume":"130","author":"van Joost","year":"1994","journal-title":"Br J Dermatol"},{"key":"key2026050211082500_ref67-bib67","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2340\/0001555570323329","article-title":"Antipruritic effect of oral cyclosporin A in atopic dermatitis","volume":"70","author":"Wahlgren","year":"1990","journal-title":"Acta Derm Venereol"},{"key":"key2026050211082500_ref68-bib68","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"key":"key2026050211082500_ref69-bib69","doi-asserted-by":"crossref","first-page":"AB404","DOI":"10.1016\/j.jaci.2013.12.1068","article-title":"Dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a 12-week, randomized, double-blind, placebo-controlled study","volume":"133","author":"Bieber","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"key2026050211082500_ref70-bib70","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"key2026050211082500_ref71-bib71","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jaad.2018.07.048","article-title":"Dupilumab does not affect correlates of vaccine-induced immunity: a randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis","volume":"80","author":"Blauvelt","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"key2026050211082500_ref72-bib72","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"key2026050211082500_ref73-bib73","first-page":"S104","article-title":"Dupilumab improved all domains of Eczema Area and Severity Index (EASI) and 5-D pruritus scale in adults with atopic dermatitis in a phase 2 study","volume":"134","author":"Hamilton","year":"2014","journal-title":"J Investig Dermatol"},{"key":"key2026050211082500_ref74-bib74","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"key2026050211082500_ref75-bib75","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(15)00388-8","article-title":"Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial","volume":"387","author":"Thaci","year":"2016","journal-title":"Lancet"},{"key":"key2026050211082500_ref76-bib76","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/bjd.15905","article-title":"Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial","volume":"178","author":"Tsianakas","year":"2018","journal-title":"Br J Dermatol"},{"key":"key2026050211082500_ref77-bib77","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study","volume":"80","author":"Guttman-Yassky","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"key2026050211082500_ref78-bib78","doi-asserted-by":"crossref","first-page":"e13685","DOI":"10.1111\/dth.13685","article-title":"The effectiveness of Janus kinase inhibitors in treating atopic dermatitis: a systematic review and meta-analysis","volume":"33","author":"Arora","year":"2020","journal-title":"Dermatol Ther"},{"key":"key2026050211082500_ref79-bib79","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/jamadermatol.2020.0796","article-title":"Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis","volume":"156","author":"Drucker","year":"2020","journal-title":"JAMA Dermatol"},{"key":"key2026050211082500_ref80-bib80","doi-asserted-by":"crossref","first-page":"e001374","DOI":"10.1136\/rmdopen-2020-001374","article-title":"Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research","volume":"6","author":"Kerschbaumer","year":"2020","journal-title":"RMD Open"},{"key":"key2026050211082500_ref81-bib81","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/jamadermatol.2020.2940","article-title":"Inclusion of older adults in randomized clinical trials for systemic medications for atopic dermatitis: a systematic review","volume":"156","author":"Lam","year":"2020","journal-title":"JAMA Dermatol"},{"key":"key2026050211082500_ref82-bib82","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaad.2018.09.053","article-title":"Relative efficacy of systemic treatments for atopic dermatitis","volume":"80","author":"Seger","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"key2026050211082500_ref83-bib83","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1111\/all.14631","article-title":"Systemic treatments in the management of atopic dermatitis: a systematic review and meta-analysis","volume":"76","author":"Siegels","year":"2021","journal-title":"Allergy"},{"key":"key2026050211082500_ref84-bib84","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1111\/jdv.17351","article-title":"Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis","volume":"35","author":"Silverberg","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key2026050211082500_ref85-bib85","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaad.2016.04.054","article-title":"Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)","volume":"75","author":"Simpson","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"key2026050211082500_ref86-bib86","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/bjd.20690","article-title":"The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study","volume":"186","author":"Zhao","year":"2022","journal-title":"Br J Dermatol"},{"key":"key2026050211082500_ref87-bib87","doi-asserted-by":"crossref","first-page":"851","DOI":"10.2340\/00015555-3219","article-title":"Dupilumab versus cyclosporine for the treatment of moderate-to-severe atopic dermatitis in adults: indirect comparison using the Eczema Area and Severity Index","volume":"99","author":"Ariens","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"key2026050211082500_ref88-bib88","doi-asserted-by":"crossref","first-page":"e13979","DOI":"10.1111\/dth.13979","article-title":"Drug survival of dupilumab compared to cyclosporin in moderate-to-severe atopic dermatitis patients","volume":"33","author":"Dal Bello","year":"2020","journal-title":"Dermatol Ther"},{"key":"key2026050211082500_ref89-bib89","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1111\/all.14324","article-title":"Two-year drug survival of dupilumab in a large cohort of difficult-to-treat adult atopic dermatitis patients compared to cyclosporine A and methotrexate: results from the BioDay registry","volume":"75","author":"Spekhorst","year":"2020","journal-title":"Allergy"},{"key":"key2026050211082500_ref90-bib90","volume-title":"Study of Abrocitinib Compared with Dupilumab in Adults with Moderate to Severe Atopic Dermatitis on Background Topical Therapy","author":"ClinicalTrials.gov","year":"2020"},{"key":"key2026050211082500_ref91-bib91","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"key2026050211082500_ref92-bib92","volume-title":"Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis \u2013 ECZTRA 5 (ECZema TRAlokinumab Trial No. 5) (ECZTRA 5)","author":"ClinicalTrials.gov","year":"2021"},{"key":"key2026050211082500_ref93-bib93","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","article-title":"Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial","volume":"145","author":"Guttman-Yassky","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"key2026050211082500_ref94-bib94","volume-title":"A Study to Evaluate Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Participants with Moderate to Severe Atopic Dermatitis (Rising Up)","author":"ClinicalTrials.gov","year":"2020"},{"key":"key2026050211082500_ref95-bib95","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjd.18898","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials","volume":"183","author":"Simpson","year":"2020","journal-title":"Br J Dermatol"},{"key":"key2026050211082500_ref96-bib96","volume-title":"A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults with Moderate to Severe Atopic Dermatitis That Are Not Controlled with Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because It Is Not Medically Advisable (BREEZE-AD4)","author":"ClinicalTrials.gov","year":"2018"},{"key":"key2026050211082500_ref97-bib97","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Reich","year":"2020","journal-title":"JAMA Dermatol"},{"key":"key2026050211082500_ref98-bib98","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/jamadermatol.2021.1273","article-title":"Long-term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials","volume":"157","author":"Silverberg","year":"2021","journal-title":"JAMA Dermatol"},{"key":"key2026050211082500_ref99-bib99","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"key2026050211082500_ref100-bib100","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1111\/bjd.16623","article-title":"Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9)","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"key":"key2026050211082500_ref101-bib101","first-page":"104","article-title":"Erratum: efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial (JAMA Dermatology (2019) 155: 12 (1371\u20131379) DOI: 10.1001\/jamadermatol.2019.2855)","volume":"156","author":"Gooderham","year":"2020","journal-title":"JAMA Dermatol"},{"key":"key2026050211082500_ref102-bib102","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1111\/bjd.18898","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the phase III, JADE MONO-1 study","volume":"183","author":"Simpson","year":"2020","journal-title":"Br J Dermatol"},{"key":"key2026050211082500_ref103-bib103","first-page":"e100","article-title":"Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: results from the phase III JADE MONO-2 study","volume":"183","author":"Silverberg","year":"2020","journal-title":"Br J Dermatol"},{"key":"key2026050211082500_ref104-bib104","first-page":"e72","article-title":"A phase III study to investigate the efficacy and safety of abrocitinib and dupilumab in comparison with placebo in adults with moderate-to-severe atopic dermatitis","volume":"184","author":"Thac-i","year":"2021","journal-title":"Br J Dermatol"},{"key":"key2026050211082500_ref105-bib105","doi-asserted-by":"crossref","first-page":"AB139","DOI":"10.1016\/j.jaad.2019.06.522","article-title":"Tralokinumab, an anti-interleukin-13 monoclonal antibody, reduces Staphylococcus aureus colonization of the skin and systemic levels of inflammatory biomarkers in atopic dermatitis patients","volume":"81","author":"Guttman\u2010Yassky","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"key2026050211082500_ref106-bib106","first-page":"e82","article-title":"Progressive and sustained improvements in the extent and severity of atopic dermatitis with tralokinumab in combination with topical corticosteroids as needed in moderate-to-severe atopic dermatitis","volume":"184","author":"Alexis","year":"2021","journal-title":"Br J Dermatol"},{"key":"key2026050211082500_ref107-bib107","doi-asserted-by":"crossref","first-page":"AB294","DOI":"10.1016\/j.jaad.2019.06.1265","article-title":"Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis from a phase 2b, randomized, controlled trial","volume":"81","author":"Guttman\u2010Yassky","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"key2026050211082500_ref108-bib108","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"key2026050211082500_ref109-bib109","first-page":"e59","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: results from the pivotal phase III, randomized, double-blind, placebo-controlled AD Up study","volume":"184","author":"Reich","year":"2021","journal-title":"Br J Dermatol"},{"key":"key2026050211082500_ref110-bib110","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"key2026050211082500_ref111-bib111","first-page":"66","article-title":"Summary of efficacy, impact on work productivity and activity, and safety of baricitinib in moderate-to-severe atopic dermatitis from two monotherapy phase III trials","volume":"183","author":"Wollenberg","year":"2020","journal-title":"Br J Dermatol"},{"key":"key2026050211082500_ref112-bib112","first-page":"69","article-title":"Dupilumab for adolescents with moderate-to-severe atopic dermatitis: results from a phase 3, randomized, double-blinded trial","volume":"60","author":"Paller","year":"2019","journal-title":"Australas J Dermatol"},{"key":"key2026050211082500_ref113-bib113","doi-asserted-by":"crossref","first-page":"AB195","DOI":"10.1016\/j.jaad.2019.06.722","article-title":"Dupilumab for adolescents with moderate-to-severe atopic dermatitis: results from a phase 3, randomized, double-blinded trial","volume":"81","author":"Paller","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"key2026050211082500_ref114-bib114","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jdermsci.2019.02.002","article-title":"Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2)","volume":"94","author":"Tha\u00e7i","year":"2019","journal-title":"J Dermatol Sci"},{"key":"key2026050211082500_ref115-bib115","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1001\/jamadermatol.2019.3617","article-title":"Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial","volume":"156","author":"Worm","year":"2020","journal-title":"JAMA Dermatol"},{"key":"key2026050211082500_ref116-bib116","volume-title":"The Newcastle\u2013Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses","author":"Wells","year":"2021"},{"key":"key2026050211082500_ref117-bib117","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/0272989X13485157","article-title":"Evidence synthesis for decision making 3: heterogeneity \u2013 subgroups, meta-regression, bias, and bias-adjustment","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"key2026050211082500_ref118-bib118","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1177\/0272989X13485155","article-title":"Evidence synthesis for decision making 5: the baseline natural history model","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"key2026050211082500_ref119-bib119","volume-title":"Early Access to Medicines Scheme \u2013 Dupilumab in the Treatment of Adolescent Patients \u2265\u200912 to <\u200918 Years of Age with Severe Atopic Dermatitis Who Have Responded Inadequately to at Least One Systemic Therapy or Where the Available Systemic Therapies Are Not Recommended or Are Not Tolerated","author":"England","year":"2019"},{"key":"key2026050211082500_ref120-bib120","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1017\/S0266462317000897","article-title":"Performance of Ovid MEDLINE search filters to identify health state utility studies","volume":"33","author":"Arber","year":"2017","journal-title":"Int J Technol Assess Health Care"},{"key":"key2026050211082500_ref121-bib121","volume-title":"SMC2232 Dupilumab 200 mg and 300 mg Solution for Injection in Pre-filled Syringe (Dupixent\u00ae)","author":"Health Improvement Scotland (HIS)","year":"2019"},{"key":"key2026050211082500_ref122-bib122","volume-title":"SMC2337 Baricitinib 2 mg and 4 mg Film-coated Tablets (Olumiant\u00ae)","author":"Health Improvement Scotland (HIS)","year":"2018"},{"key":"key2026050211082500_ref123-bib123","volume-title":"CADTH Drug Reimbursement Review Dupilumab (Dupixent)","author":"Anonymous","year":"2018"},{"key":"key2026050211082500_ref124-bib124","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s13555-017-0201-6","article-title":"Economic evaluation of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults","volume":"7","author":"Kuznik","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"key":"key2026050211082500_ref125-bib125","first-page":"750","article-title":"Economic evaluation of dupilumab for moderate-to-severe atopic dermatitis: a cost\u2013utility analysis","volume":"17","author":"Zimmermann","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"key2026050211082500_ref126-bib126","unstructured":"Institute for Clinical and Economic Review (ICER). Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value. 2017. URL: https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/MWCEPAC_ATOPIC_EVIDENCE_REPORT_051217.pdf (accessed 1 August 2021)."},{"key":"key2026050211082500_ref127-bib127","unstructured":"Institute for Clinical and Economic Review (ICER). JAK Inhibitors and Monoclonal Antibodies for the Treatment of Atopic Dermatitis: Effectiveness and Value. 2021. URL: https:\/\/icer.org\/wp-content\/uploads\/2020\/12\/ICER_Atopic-Dermatitis_Draft-Evidence-Report_051421.pdf (accessed 4 November 2021)."},{"key":"key2026050211082500_ref128-bib128","doi-asserted-by":"crossref","first-page":"S412","DOI":"10.1016\/j.jval.2020.08.089","article-title":"PBI11 Cost-effectiveness analysis of dupilumab for the treatment of atopic dermatitis in adolescent patients in Italy","volume":"23","author":"Fanelli","year":"2020","journal-title":"Value Health"},{"key":"key2026050211082500_ref129-bib129","volume-title":"SMC2011 Dupilumab 300\u2009mg Solution for Injection in Pre-filled Syringe (Dupixent\u00ae)","author":"Health Improvement Scotland (HIS)","year":"2018"},{"key":"key2026050211082500_ref130-bib130","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/bjd.18451","article-title":"Higher self-reported severity of atopic dermatitis in adults is associated with poorer self-reported health-related quality of life in France, Germany, the U.K. and the U.S.A","volume":"182","author":"Andersen","year":"2020","journal-title":"Br J Dermatol"},{"key":"key2026050211082500_ref131-bib131","first-page":"269","article-title":"The impact of atopic dermatitis on health-related quality of life in Taiwan","volume":"21","author":"Hsieh","year":"2021","journal-title":"J Formos Med Assoc"},{"key":"key2026050211082500_ref132-bib132","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s12325-021-01630-z","article-title":"Psychosocial comorbidities and health status among adults with moderate-to-severe atopic dermatitis: a 2017 US National Health and Wellness Survey Analysis","volume":"38","author":"Kwatra","year":"2021","journal-title":"Adv Ther"},{"key":"key2026050211082500_ref133-bib133","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2340\/00015555-2940","article-title":"Patient burden is associated with alterations in quality of life in adult patients with atopic dermatitis: results from the ECLA study","volume":"98","author":"Misery","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"key2026050211082500_ref134-bib134","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s13555-020-00459-8","article-title":"The economic and psychosocial comorbidity burden among adults with moderate-to-severe atopic dermatitis in Europe: analysis of a cross-sectional survey","volume":"11","author":"Girolomoni","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"key2026050211082500_ref135-bib135","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s11136-019-02174-0","article-title":"Process utilities for topical treatment in atopic dermatitis","volume":"28","author":"Retzler","year":"2019","journal-title":"Qual Life Res"},{"key":"key2026050211082500_ref136-bib136","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jaip.2018.11.043","article-title":"Health utility scores of atopic dermatitis in US adults","volume":"7","author":"Silverberg","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"key2026050211082500_ref137-bib137","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s13555-017-0181-6","article-title":"Dupilumab improves general health-related quality-of-life in patients with moderate-to-severe atopic dermatitis: pooled results from two randomized, controlled phase 3 clinical trials","volume":"7","author":"Simpson","year":"2017","journal-title":"Dermatol Ther (Heidelb)"},{"key":"key2026050211082500_ref138-bib138","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jaad.2015.10.043","article-title":"Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults","volume":"74","author":"Simpson","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"key2026050211082500_ref139-bib139","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.clinthera.2019.02.007","article-title":"Estimation of health utilities based on the response to treatment in atopic dermatitis: a population-based study","volume":"41","author":"Song","year":"2019","journal-title":"Clin Ther"},{"key":"key2026050211082500_ref140-bib140","doi-asserted-by":"crossref","first-page":"AB125","DOI":"10.1016\/j.jaad.2019.06.473","article-title":"Societal burden of atopic dermatitis in the US population","volume":"81","author":"Silverberg","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"key2026050211082500_ref141-bib141","doi-asserted-by":"crossref","first-page":"AB254","DOI":"10.1016\/j.jaad.2017.04.988","article-title":"The impact of severity of atopic dermatitis on patient-reported outcomes of adults with moderate-to-severe atopic dermatitis","volume":"76","author":"Vietri","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key2026050211082500_ref142-bib142","first-page":"334","article-title":"Greater severity of atopic dermatitis (AD) is associated with poorer patient reported outcomes among adults with moderate-to-severe AD","volume":"27","author":"Nyberg","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"key2026050211082500_ref143-bib143","doi-asserted-by":"crossref","first-page":"S433","DOI":"10.1016\/j.jval.2018.09.2561","article-title":"Process utilities for topical treatment in atopic dermatitis","volume":"21","author":"Retzler","year":"2018","journal-title":"Value Health"},{"key":"key2026050211082500_ref144-bib144","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"key":"key2026050211082500_ref145-bib145","volume-title":"Guide to the Methods of Technology Appraisal 2013","author":"National Institute for Health and Care Excellence (NICE)","year":"2013"},{"key":"key2026050211082500_ref146-bib146","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1524-4733.2010.00700.x","article-title":"Populating an economic model with health state utility values: moving toward better practice","volume":"13","author":"Ara","year":"2010","journal-title":"Value Health"},{"key":"key2026050211082500_ref147-bib147","volume-title":"Neoral Soft Gelatin Capsules. Summary of Product Characteristics","author":"Electronic Medicines Compendium (emc)","year":"2021"},{"key":"key2026050211082500_ref148-bib148","volume-title":"Unit Costs of Health and Social Care 2020, Personal Social Services Research Unit, University of Kent, Canterbury","author":"Curtis","year":"2020"},{"key":"key2026050211082500_ref149-bib149","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22570","article-title":"Adding emollient bath additives to standard eczema management for children with eczema: the BATHE RCT","volume":"22","author":"Santer","year":"2018","journal-title":"Health Technol Assess"},{"key":"key2026050211082500_ref151-bib151","volume-title":"Drugs and Pharmaceutical Electronic Market Information Tool (eMIT)","author":"Department of Health and Social Care","year":"2021"},{"key":"key2026050211082500_ref152-bib152","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.14888","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II","volume":"32","author":"Wollenberg","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key2026050211082500_ref153-bib153","volume-title":"National Schedule of NHS Costs \u2013 Year 2019\u201320 \u2013 NHS Trusts and NHS Foundation Trusts","author":"NHS Improvement","year":"2020"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2044693","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/LEXB9006\/LEXB9006.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2044693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T14:39:47Z","timestamp":1777732787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/LEXB9006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":149,"alternative-id":["10.3310\/LEXB9006"],"URL":"https:\/\/doi.org\/10.3310\/lexb9006","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"08-2021","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"02-2022","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"02-2023","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}